ALK and cancer: Several previous papers showed that inhibiting MK by small interfering RNA could exert obvious therapeutic effects in cancer models.[29–30] At the same time, MK inhibitors were also being explored,[31] which have been successfully applied to several cancer models recently as well.[32–34] Major underlying mechanism involved suppressing MAPK, PI3K, or ERK 1/2 pathways through ALK or PTP ζ receptors.